Kailiang Wu

Dr. Kailiang Wu


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2010 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
KZKuai-Le Zhao
Kuai-Le Zhao
JMJin-Bo Ma
Jin-Bo Ma
GLGuang Liu
Guang Liu
KWKailiang Wu
Kailiang Wu
XSXue-Hui Shi
Xue-Hui Shi
GJGuo-Liang Jiang
Guo-Liang Jiang

1 December 2003 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
KWKailiang Wu
Kailiang Wu
GJGuo-Liang Jiang
Guo-Liang Jiang
HQHao Qian
Hao Qian
LWLi-Juan Wang
Li-Juan Wang
HYHuan-Jun Yang
Huan-Jun Yang
SZShen Zhao
Shen Zhao

1 July 2010 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
KWKailiang Wu
Kailiang Wu
YUYee C. Ung
Yee C. Ung
JHJennifer Hornby
Jennifer Hornby
MFMarc Freeman
Marc Freeman
DHDavid Hwang
David Hwang
SWShun Wong
Shun Wong

1 April 2007 in Lung Cancer
Verified
Journal Article
Closed access
TCTing-Feng Chen
Ting-Feng Chen
GJGuo-Liang Jiang
Guo-Liang Jiang
XFXiao-Long Fu
Xiao-Long Fu
LWLi-Juan Wang
Li-Juan Wang
HQHao Qian
Hao Qian
SZSen Zhao
Sen Zhao

29 December 2022 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
YLYaqi Li
Yaqi Li
XFXingwen Fan
Xingwen Fan
QYQi Yu
Qi Yu
HZHaoyang Zhai
Haoyang Zhai
MMMiao Mo
Miao Mo
KWKailiang Wu
Kailiang Wu
Lymphopenia is a common adverse effect of radiation therapy (RT). Little is known about the difference in lymphopenia between intensity modulated (photon) radiation therapy (IMRT) and proton and carbon ion radiation therapy (PCIRT). This study aimed to investigate lymphopenia differences between IMRT and PCIRT in non-small cell lung cancer (NSCLC). Clinical and dosimetric parameters were collected from 343 patients who received definitive IMRT or PCIRT for NSCLC. Severe lymphopenia (SRL) was defined as an absolute lymphocyte count (ALC) ≤0.5 × 103 cells/μL. Overall survival (OS) was analyzed using the Kaplan-Meier method. Propensity score matching was performed between the IMRT and PCIRT groups. Least absolute shrinkage and selection operator analysis was used to select appropriate dosimetric parameters. Univariate and multivariate logistic regression analyses were conducted to identify the predictors of SRL. Compared with the IMRT group, the PCIRT group was less likely to develop SRL (P < .001). Compared with the non-SRL group, the SRL group showed significant association with poorer OS, with a median survival time of 29.2 versus 15.0 months (P = .046). IMRT was an independent risk factor of SRL (P = .004). A lower ALC before RT (P = .030) and larger planning target volume (PTV) (P = .002) were also significant independent risk factors for SRL. Moreover, the majority of dosimetric parameters of organs at risk in PCIRT were lower than those in IMRT (P < .001). Thoracic vertebra V5 (P = .002) and aorta V5 (P = .026) were identified as independent risk predictors of SRL after adding dosimetric parameters to the regression model. Compared with IMRT, PCIRT could reduce SRL incidence, possibly by limiting thoracic vertebra and aortic doses, and SRL was associated with poor outcomes in patients with NSCLC.

1 March 2015 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
BXBing Xia
Bing Xia
LHLing-Zhi Hong
Ling-Zhi Hong
XCXu-Wei Cai
Xu-Wei Cai
ZZZheng-Fei Zhu
Zheng-Fei Zhu
QLQi Liu
Qi Liu
XFXiaolong Fu
Xiaolong Fu